Presidential Session

[PS-2] Durvalumab consolidation treatment（tx）in limited-stage SCLC：ADRIATIC Japanese subgroup analysis

^○Yoshitaka Zenke¹, Isamu Okamoto², Yuichiro Ohe³, Koichi Azuma⁴, Kyoichi Okishio⁵, Hirokazu Ogino⁶, Yoshitsugu Horio⁷, Satoshi Oizumi⁸, Manabu Hayama⁹, Masatoshi Sugeno¹⁰, Masaya Harada⁹, Yuka Olivo¹¹, Haiyi Jiang¹², Suresh Senan¹³ (1.National Cancer Center Hospital East, Kashiwa, Japan, 2.Kyushu University Hospital, Fukuoka, Japan, 3.National Cancer Center Hospital, Tokyo, Japan, 4.Kurume University Hospital, Kurume, Japan, 5.National Hospital Organization Kinki-chuo Chest Medical Center, Sakai, Japan, 6.Tokushima University Hospital, Tokushima, Japan, 7.Aichi Cancer Center Hospital, Nagoya, Japan, 8.Hokkaido Cancer Center, Sapporo, Japan, 9.AstraZeneca K.K., Minato-ku, Tokyo, Japan, 10.AstraZeneca K.K., Kita-ku, Osaka, Japan, 11.AstraZeneca, New York, NY, USA, 12.AstraZeneca, Gaithersburg, MD, USA, 13.Amsterdam University Medical Centers, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, Amsterdam, the Netherlands)